36
Participants
Start Date
July 30, 2025
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
CV09070101 mRNA vaccine (CVHNLC) 50 µg
CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
CV09070101 mRNA vaccine (CVHNLC) 100 µg
CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
CV09070101 mRNA vaccine (CVHNLC) 200 µg
CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
CV09070101 mRNA vaccine (CVHNLC) 400 µg
CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
CV09070101 mRNA vaccine (CVHNLC) 400 µg
CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly) and carboplatin/paclitaxel (3-weekly)
Virginia Cancer Center, Fairfax
Virginia Commonwealth University, Massey Comprehensive Cancer Center, McGlothlin Medical Education Center, Richmond
AP-HM - Hôpital Nord, Marseille
Institut Curie - Hôpital de Paris, Paris
CHU de Rennes - Hôpital Pontchaillou, Rennes
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS, Saint-Herblain
Institut Claudius Regaud - PPDS, Toulouse
Gustave Roussy, Villejuif
Hospital Quironsalud Barcelona -NEXT Oncology, Barcelona
Hospital Universitari Vall d´Hebron -Instituto de Investigacion Oncologica Vall dHebron (VHIO), Barcelona
Hospital Universitario Fundacion Jimenez Diaz - START MADRID, Madrid
Hospital Universitario HM Sanchinarro - CIOCC - START MADRID, Madrid
Hospital Regional Universitario Virgen de la Victoria, Málaga
Lead Sponsor
CureVac
INDUSTRY